<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555749</url>
  </required_header>
  <id_info>
    <org_study_id>NN7415-3981</org_study_id>
    <secondary_id>2011-004575-36</secondary_id>
    <secondary_id>U1111-1124-5137</secondary_id>
    <nct_id>NCT01555749</nct_id>
  </id_info>
  <brief_title>Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single Centre, Single Dose Trial, Assessing the Pharmacokinetics of NNC172-2021, Administered Subcutaneously at Two Different Dose Levels, in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the&#xD;
      pharmacokinetics (how the trial drug is distributed in the body) of NNC172-2021 administered&#xD;
      subcutaneously, at two different dose levels, in healthy Japanese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2012</start_date>
  <completion_date type="Actual">May 8, 2012</completion_date>
  <primary_completion_date type="Actual">May 8, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from time point 0 to infinity (AUC0-âˆž) of NNC172-2021</measure>
    <time_frame>Week 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal concentration of NNC172-2021 (Cmax)</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time point for maximal concentration (tmax)</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of antibodies against NNC172-2021</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual tissue factor pathway inhibitor (TFPI) functionality measured by coagulation factor Xa (FXa) generation</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TFPI concentration measured by tissue factor pathway inhibitor (TFPI) enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NNC172-2021 low dose / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC172-2021 high dose / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC172-2021</intervention_name>
    <description>One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL</description>
    <arm_group_label>NNC172-2021 high dose / Placebo</arm_group_label>
    <arm_group_label>NNC172-2021 low dose / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>One injection administered subcutaneously (s.c., under the skin)</description>
    <arm_group_label>NNC172-2021 high dose / Placebo</arm_group_label>
    <arm_group_label>NNC172-2021 low dose / Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male Japanese subjects defined as: Subjects born in Japan, time residing&#xD;
             outside of Japan does not exceed 5 years, both parents and all 4 grandparents of&#xD;
             Japanese descent&#xD;
&#xD;
          -  Body weight between 50 and 100 kg, both inclusive&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 30.0 kg/m^2, both inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male subjects who are sexually active and not surgically sterilised who, or whose&#xD;
             partner, are unwilling to use two different forms of effective contraception, one of&#xD;
             which has to be a barrier method of contraception (e.g. condom with spermicidal&#xD;
             foam/gel/film/cream) for the duration of the trial and for 3 months following the last&#xD;
             dose of trial medication&#xD;
&#xD;
          -  Planned surgery 30 days prior to trial product administration and/or during the entire&#xD;
             trial period&#xD;
&#xD;
          -  Known hepatic dysfunction during the last 12 months prior to screening (Visit 1)&#xD;
&#xD;
          -  Positive urine test for drugs of abuse&#xD;
&#xD;
          -  Active hepatitis B and/or hepatitis C infection&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Subjects with clinical signs of thromboembolic events, considered to be at high risk&#xD;
             of thromboembolic event or subjects with a known first degree family history of&#xD;
             thromboembolism&#xD;
&#xD;
          -  Participation in any other trial investigating other products or involving blood&#xD;
             sampling within the last 30 days prior to screening&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid&#xD;
             (ASA), but not ibuprofen and cyclooxygenase-2 (COX-2) specific inhibitors within 2&#xD;
             weeks prior to trial product administration (Visit 2)&#xD;
&#xD;
          -  Positive alcohol test at screening (Visit 1) and/or history of alcohol or drug abuse&#xD;
             within the last 12 months prior to screening (Visit 1)&#xD;
&#xD;
          -  Smokers; defined as tobacco users smoking more than 5 cigarettes per day or the&#xD;
             corresponding amount of tobacco consumption&#xD;
&#xD;
          -  Blood donation within the last 3 months prior to screening and/or during the entire&#xD;
             trial period&#xD;
&#xD;
          -  Strenuous exercise (as judged by the trial physician) within the last 4 days prior to&#xD;
             screening (Visit 1)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

